secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001935979-25-000090
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven reports Q3 net loss $173.4M, plans 60% R&D spend cut to focus on three late-stage programs
--------------------------------------------------------------------------------

- Net loss $173.4M ($1.64/share) vs $160.3M ($1.70/share) YoY; non-GAAP loss $155.9M ($1.47/share).
- R&D spend $141.2M, down 10% YoY; plans ~60% reduction in direct R&D spend going forward.
- Cash and equivalents $263.8M as of Sep 30, 2025.
- Restructuring: focus on opakalim (Kv7), extracellular degraders (BHV-1400/1300), and taldefgrobep (myostatin); other programs paused/halted.
- FDA Type A meeting requested to appeal CRL for SCA drug VYGLXIA; Phase 2 opakalim depression data expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/0001935979-25-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/bhvn-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001935979-25-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer